Avacta Share Discussion Threads

[bonzo] 02/10/2017 08:41

US BD has to be key element got Avacta to succeed, looks as if they have a good team...

[mrangry2] 29/9/2017 16:46

Just a serious attack of impatience I think.

[poacher45] 29/9/2017 15:52

Once again it will be the same old story sales up but expenses up by a hell of a lot more. There is just no control.

[the drewster] 29/9/2017 15:46

or someone's got early access to next week's announcement.

Disappointing.

[lantanatony] 29/9/2017 14:49

Looks like there's a substantial seller about?

[the drewster] 21/9/2017 19:41

Opening research doors that "previous science" had, as yet, been unable to open.

Further validation, but not the transformational commercial traction deal that we all long for.

[lantanatony] 21/9/2017 18:20

More good news today!
Keep the faith.

[lantanatony] 07/9/2017 15:44

I agree it sure looks like good news to me.
Why are Avacta not making more of it?!

[the drewster] 06/9/2017 15:56

It spells, or at least potentially, the end of the reproducibility crisis ... it is something quite astounding that seems lost on Mr Market.

Imagine as a provider of diagnostics, or therapuetics (which is where it gets more interesting) being able to increase the incidence of your antibody, or antibody based compound, binding only the target proteins. Increase effective response while decrease the chance of unwanted bindings (potential side effects).

[lantanatony] 06/9/2017 13:45

Drewster
I agree this is all good stuff,but we need some better market traction.
You would think a company from the sector would pay good money for such an assay?!

[the drewster] 05/9/2017 11:12

Well worth a read:

"A new paper (link is external) published recently in the Nature group journal, Scientific Reports, demonstrates the ability to combine the use of Affimers with antibodies to increase specificity and performance of a diagnostic tests against glypican-3, a cancer biomarker. The work was carried out by the Southern Medical University, Guangzhou in collaboration with the University of Leeds. The new assay offers a significant increase in specificity with results aligned to the ‘gold standard’ invasive immunohistochemical assay. The performance improvement observed with this new assay potentially provides a non-invasive test for monitoring cancer patients."

Full article here:

[the drewster] 25/8/2017 15:40

Any one significant deal from any one of the many irons in the fire could be transformational, but an in-house cancer therapeutic with promising trials would send this into the multi-bagger territory. Not so long (in medical research terms) to wait.
I'm happy with the various technical milestones that are being reached, and hope it's just a matter of time before the market wakes up to the technology and potential financial value.

[18bt] 25/8/2017 07:45

Malcom Stacey has tipped on Share Prophets yesterday pointing to Alastair Smith's purchase. Not ure whether Shre Prophets counts as a credible tip!!

[lantanatony] 24/8/2017 23:41

Interesting and I agree it is very sad reading but I feel there are very different eyes on the company now.
But as I have said before ....
It's just a punt!

[the drewster] 24/8/2017 16:45

Some history ...

2006 issue 4.5m shares at 225 on readmission - Mkt Cap £14.5m

2008 issued shares at prices above 500 to buy Oxford Medical Diagnostics ltd ... market cap then around £45m in March 2008

Subsequent cash raising activity:
£2m @ 150 October 09
£1.95m @ 105 January '11
£4.7m @ 55 July '13
£10m @ 110 May '14
£22m @ 125 July '15

Weighted average, £40.65m @ 105

Update end July '17, that cash is c.£13m. Share price around 75p and Market Cap at about £52m

[lantanatony] 21/8/2017 23:56

Bypooh
I did very well out of Internet shares by following the big investors in and not so bad out of the Banks for the same reason.
But if you know better, then so be it.

[lantanatony] 21/8/2017 23:56

Bypooh
I did very well out of Internet shares by following the big investors in and not so bad out of the Banks for the same reason.
But if you know better, then so be it.

[poacher45] 21/8/2017 19:17

Perhaps that is the only way he can get another rights issue off the ground. Just my opinion.

[tratante] 21/8/2017 14:40

CEO is positive, just bought 33k's worth.

[the drewster] 21/8/2017 08:48

£1.25??? ... It was £1.40 wasn't it?

[escapetohome] 20/8/2017 16:00

Institutional investors are not risking their own money, they play around with yours.

[bypooh] 20/8/2017 14:19

lantanatony

That is about as daft a comment as you can make. Practically all quoted companies have institutional investors. That does not seem to correlate with success. As for expertise, you must be joking. The same experts that created the internet bubble? Those that chased bank shares until they blew up? Those geniuses that stumped up £1.25 per share of Avacta two years ago?

[lantanatony] 12/8/2017 22:20

Wan
I am still waiting for your response to.why you think the institutional share holders are not picking up on your views.
They have expert advice while you work in the property sector.
Everyone can heve their say,but what makes you an expert?

[danatkins] 12/8/2017 15:12

Wam I am grateful for your input its good to highlight other areas of interest which may have an affect on Avacta's goals. I recognise the risks but also the opportunity. Competition is the cornerstone of hunman achievement. We shall see soon what we have I guess within the next year.